

# Multiple Cancer Prevention and Control Workgroup

Leads: Karen Glanz, PhD, MPH  
Jade Avelis, PhD  
University of Pennsylvania



This website is supported by the Centers for Disease Control and Prevention of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award with 100 percent funded by CDC/HHS (Cooperative Agreement Number U48 DP006400). The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by CDC/HHS, or the U.S. Government.

# Members and Reviewers

## UPenn:

Karen Glanz

Jade Avelis

## UNC:

Stephanie Wheeler

## Washington:

Peggy Hannon

Thuy Vu

## New Mexico:

Prajakta Adsul

## Emory:

Cam Escoffery

## NIH/NCI:

David Chambers

Cynthia Vinson

## CDC:

Susan Sabatino

## Texas:

Maria Fernandez

## Reviewers:

Prajakta Adsul

Jade Avelis

Cam Escoffery

Maria Fernandez

Princess Ogidi (UPenn)

Susan Sabatino

Lara Savas (Texas)

Cynthia Vinson

# Background and Rationale

- Ensuring proper screening is a challenge in cancer prevention and control
- Most interventions focus on a single type of cancer
- Opportunity exists to increase efficiency by “clustering” or “bundling” multiple cancer screening efforts together. Some examples include:
  - Presenting them as a single package during one office appointment
  - Attaching them to an already well-established appointment
- Similar existing programs: FluFIT and WiseWoman

# Scoping review

- Intended to provide an overview of available research on a topic
- Distinct from a systematic review

## Research Questions

- Primary
  - What is the structure, content, and impact of bundled cancer screening programs?
- Secondary
  - What cancers are commonly bundled together?
  - What are the implementation strategies used?
  - How have programs been evaluated?
  - How is impact measured with these studies?
  - What outcomes have been evaluated?

# Inclusion Criteria

- Written in English
- Published 1975-2018
- Describes a proposed or implemented model/program that does one of the following:
  - Bundles cancer screenings for two different sites (e.g., breast and cervical)
  - Bundles a cancer screening with a non-cancer preventive care service (e.g., FluFIT)
- International studies should be included
- Only original research
  - Reviews should be marked for informational purposes
- Studies that use secondary data analysis of national datasets should be included as long as they analyze the topic of interest
- Include articles that study the promotion of different screenings; may be excluded later

# Exclusion Criteria

- Model/program is for high risk population
- Model/program is primarily about genetic screening
- Model/programs is about PSA testing or lung cancer screening

Search terms used included: ("neoplasms" or "cancer") AND ("papanicolaou" or "colorectal neoplasms" or "breast neoplasms" or "uterine cervical neoplasms" or "Human Papillomavirus DNA Tests" or "mammography" or "colonoscopy" or "sigmoidoscopy" or "fecal immunochemical test" or "fecal occult blood test") AND (combined or multiple or packaged or package or packaging or bundle or bundled or bundling)) AND ("early detection of cancer" or "mass screening" or "screening")

Identification

Records identified through  
database searching  
(n = 2820)

Additional records identified  
through other sources  
(n = 3)

Records  
(n = 2823)

Screening

Titles and abstracts  
screened  
(n = 2823)

Records excluded  
(n = 2768)

Full-text Review

Full-text articles to be  
screened  
(n = 55)

# Activity

- Reviewed the abstracts and titles of ~2,800 articles
- Identified 55 articles for full-text review
- Created online abstracting sheet
- Distributing assignments for full-text reviews (Jan. 2021)
- Proposed timeline
  - January-March 2021: Complete review of articles
  - April-May 2021: Chart and organize data
  - June-August 2021: Summarize and report results
  - September-November 2021: Manuscript preparation
  - December 2021: Submit review for publication